CRISPR-Cas-based activation of PPARGC1A boosts endogenous mitochondria and enhances cardiac function after myocardial infarction
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2026.02.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Mario Escobar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Rice University, Houston, TX 77005, USA; Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston,…. Hauptthemen laut MEDLINE: Myocardial Infarction, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, CRISPR-Cas Systems, Mitochondria. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, American Heart Association-American Stroke Association.
Abstract (Originalsprache)
Insufficient energy supply due to impaired mitochondria has emerged as a key pathological factor in the development of heart failure (HF) after myocardial infarction (MI). Unfortunately, no current therapeutic strategies directly augment myocardial energy production. While mitochondrial biogenesis is orchestrated by the activity of multiple genes, activation of PPARGC1A, a key regulator, can increase cellular mitochondria; however, supraphysiological levels of PPARGC1A result in adverse tissue remodeling and heart dysfunction. CRISPR activation (CRISPRa) technologies present a unique opportunity to address these shortcomings, as they enable tunable control over endogenous target gene expression. Here, we demonstrate that transcriptional activation of PPARGC1A using CRISPRa increases cellular mitochondria in human cell types. This effect is mediated through the activation of transcriptional programs driving mitochondrial biogenesis, mitochondrial function, and cellular bioenergetics. These activated transcriptional programs synergize to increase ATP production and reserve capacity in human cardiomyocytes. CRISPRa targeting of PPARGC1A in vivo increases cardiac mitochondria to recover heart ejection fraction in an acute MI model. Furthermore, CRISPRa acts on the adult human heart to increase PPARGC1A protein and cellular mitochondria, elevating mitochondrial function in both normal and HF-diagnosed hearts. These results provide the first proof of concept that endogenous gene activation via CRISPRa can improve heart function after MI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, Rice University, Houston, TX 77005, USA; Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: mario.escobar@rice.edu.
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
- Department of Bioengineering, Rice University, Houston, TX 77005, USA.
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: ghanta@bcm.edu.
- Department of Bioengineering, Rice University, Houston, TX 77005, USA; Department of BioSciences, Rice University, Houston, TX 77005, USA; Rice Synthetic Biology Institute, Rice University, Houston, TX 77005, USA. Elect…
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- American Heart Association-American Stroke Association
- American Heart Association Inc
- ZOLL Foundation
- Department of Surgery
- National Institutes of Health
Zitieren
APA
Escobar, M., Malik, S. A., Srinivasa, M. A., Mendez-Sosa, M. A., Miller, J. M., Lydon, S. L., Luong, S. N., Mathew, P. R., Abouleisa, R. R. E., Chakravarty, S., Pathan, S., Mohamed, T. M. A., Ghanta, R. K., & Hilton, I. B. (2026). CRISPR-Cas-based activation of PPARGC1A boosts endogenous mitochondria and enhances cardiac function after myocardial infarction. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.02.027
Vancouver
Escobar M, Malik SA, Srinivasa MA, Mendez-Sosa MA, Miller JM, Lydon SL, et al. CRISPR-Cas-based activation of PPARGC1A boosts endogenous mitochondria and enhances cardiac function after myocardial infarction. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.02.027
BibTeX
@article{Escobar2026,
author = {Escobar, Mario and Malik, Saad A and Srinivasa, Mira A and Mendez-Sosa, Miguel A and Miller, Jessica M and Lydon, Samantha L and Luong, Sandy N and Mathew, Pretty R and Abouleisa, Riham R E and Chakravarty, Suridh and Pathan, Saliha and Mohamed, Tamer M A and Ghanta, Ravi K and Hilton, Isaac B},
title = {CRISPR-Cas-based activation of PPARGC1A boosts endogenous mitochondria and enhances cardiac function after myocardial infarction},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.02.027}
}
EUVIMED